Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Alder, Umia and the founders in connection with the sale of Umia Innovation to TSG
Mandate

Vinge advises Alder, Umia and the founders in connection with the sale of Umia Innovation to TSG

September 15, 2023 M&A

Vinge has advised Alder, Umia and the founders in connection with the sale of Umia Innovation to The Specialist Group (TSG), a portfolio company of Oaktree Capital Management.

Umia Innovation, with offices located in Umeå, Skellefteå och Örnsköldsvik, provides knowledge-based consultancy services within processing, technology and leadership. The company has customers within, among other things, the mining industry, forestry, medical technology, the car industry and the energy sector. Umia Innovation has changed its name to Altio in connection with the transaction.

Vinge’s team primarily consisted of Johan Larsson, Karl Klackenberg, Ellinor Wargenbrant, Carl Fredrik Wachtmeister, Robin Fagerström (M&A), as well as Jessica Henning and Emy Rydén (project assistants).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025